Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26025561.
- Also identified by DOI 10.1158/1078-0432.CCR-15-0363 and PMC identifier 4506225.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.
Medical subject headings
- B7-H1 Antigen
- Lymphocytes, Tumor-Infiltrating
- Melanoma
- Protein Kinase Inhibitors